Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Lymphoid 1Breast 1

Conditions

Stomach Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 135Fluorouracil 129Gemcitabine 114Bevacizumab 111Specimen Handling 101Leucovorin 101Capecitabine 87Magnetic Resonance Spectroscopy 81pembrolizumab 78Cisplatin 74Nivolumab 70Irinotecan 68Cetuximab 58130-nm albumin-bound paclitaxel 58durvalumab 57Paclitaxel 57Biopsy 55atezolizumab 42Radiotherapy 40Albumin-Bound Paclitaxel 36Taxes 35Folfox protocol 34Carboplatin 34Drug Therapy 28lenvatinib 27sintilimab 26dehydroftorafur 26Radiation 26Cyclophosphamide 26tislelizumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
AP 1903 reagent × Gastrointestinal × 90 days × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07509008 2026-05-05

Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
10 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡